市场调查报告书
商品编码
1403481
2030 年质子治疗系统市场预测:按产品类型、类型、设定、适应症、最终用户和地区进行的全球分析Proton Therapy Systems Market Forecasts to 2030 - Global Analysis By Product Type, Type, Set-Up, Indication, End User and By Geography |
根据 Stratistics MRC 的数据,全球质子治疗系统市场在预测期内将以 15.6% 的复合年增长率成长。
质子治疗系统是专为精准癌症治疗而设计的先进医疗技术,可提高癌症患者的治疗效果和生活品质。质子治疗可以将剂量与肿瘤的形状精确匹配,从而可以向癌细胞输送更高的剂量,同时不伤害健康组织。
据世界卫生组织 (WHO) 称,癌症是全球头号死亡原因,到 2020 年将导致约 1,000 万人死亡。
质子治疗作为放射治疗的一种先进型态,在癌症治疗中具有多种优势。它使用质子束精确瞄准肿瘤并提供高剂量的辐射,同时对周围健康组织的损害最小。这种有针对性的方法降低了与传统放射线治疗相关的副作用和长期併发症的风险。质子束治疗被认为是一种有价值的治疗方法,因为它可以实现精确且准确的放射照射,并且市场需求不断增加。
儘管质子治疗是一种先进且有效的治疗方法,但与传统的放射治疗设施相比,质子治疗中心的可用性和可近性受到限制。质子治疗中心的地理分布在限制访问方面发挥了作用。此外,由于距离遥远且附近缺乏设施,居住在偏远或农村地区的患者在接受质子治疗时可能面临重大挑战。因此,缺乏准入是阻碍市场拓展的主要因素。
质子治疗机设计和功能的改进与复杂的治疗计划系统相结合,使医疗保健提供者能够提供高度针对性的放射剂量。先进成像技术的整合透过即时可视化肿瘤和周围健康组织来提高治疗精度。此外,治疗计划的软体创新优化了质子治疗,以满足个别患者的需求,促进个体化和适应性的方法。因此,这些技术创新将加速市场的成长。
虽然质子治疗具有独特的优势,但强度调控放射治疗(IMRT) 和立体定位放射治疗 (SBRT) 等替代技术已取得重大进展,但在某些情况下可能无法提供可比较的治疗结果。调强放射治疗(IMRT)是一种广泛采用的放射治疗治疗方法,它使用多个放射束,可以客製化放射束以向肿瘤提供精确的剂量,同时最大限度地减少对周围健康组织的暴露。替代技术的可用性是市场扩张的一个挑战。
由于 COVID-19大流行,质子治疗系统市场正在经历重大影响。大流行期间医疗保健预算的财务压力可能会影响投资决策并减缓质子治疗系统的采用。但大流行激发了创新和适应。远端医疗解决方案越来越多地用于患者咨询和随访。人们越来越认识到质子治疗的好处,包括减少治疗相关的副作用,强调了先进癌症治疗方法的重要性。
预计旋转质子束治疗系统领域将占最大份额。旋转质子治疗系统利用可以围绕患者旋转的机架,提供从不同角度向肿瘤提供辐射的3D方法。这种动态旋转可以更精确地靶向癌细胞,同时最大限度地减少与健康组织的接触。此外,质子束可以从多个方向发射,这提高了其对肿瘤形状的符合性,使其对形状复杂且不规则的肿瘤特别有效。
预计光束传输系统领域在预测期内将出现良好的成长。此系统负责引导和控制来自质子加速器的高能量质子束照射到患者体内的肿瘤部位。质子束的深度和强度由能量调变、磁铁和准直器等组件的组合来成形和调变。此外,现代光束传输系统通常采用扫描或点扫描技术,可逐点传输质子束,以实现更高的精度。
在估计期间,北美占据了最大的市场占有率。癌症发生率的增加以及人们对质子治疗益处的认识不断提高,正在推动这些先进系统的采用。美国着名的癌症治疗中心和研究机构的存在创造了一个创新和技术采用的环境,从而促进了质子治疗解决方案的开发和部署。此外,学术界、医疗机构和行业相关人员之间的合作正在促进质子治疗研究的进步和最佳实践的普及。
预计欧洲在预测期内将出现盈利成长。由于癌症发病率上升以及对创新医疗技术的日益重视,德国、英国和英国等欧洲国家对质子治疗系统表现出了强劲的需求。此外,该地区还拥有领先的癌症治疗中心和研究机构网络,积极致力于先进质子治疗解决方案的开发和应用。
According to Stratistics MRC, the Global Proton Therapy Systems Market is growing at a CAGR of 15.6% during the forecast period. Proton therapy systems are advanced medical technologies designed for precise cancer treatment, offering enhanced therapeutic effectiveness and an improved quality of life for cancer patients. Proton therapy allows for precise dose conformity to the shape of the tumor, enabling higher radiation doses to be delivered to the cancer cells while sparing healthy tissues.
According to the WHO (World Health Organization), cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020.
Proton therapy, as an advanced form of radiation therapy, offers several advantages in cancer treatment. It utilizes protons to precisely target tumours, delivering higher radiation doses while minimizing damage to surrounding healthy tissues. This targeted approach reduces the risk of side effects and long-term complications associated with conventional radiation therapy. Proton therapy, with its ability to provide precise and accurate radiation delivery, has gained recognition as a valuable treatment modality, which enhances market demand.
While proton therapy is an advanced and effective treatment modality, the availability and accessibility of proton therapy centers are limited compared to conventional radiation therapy facilities. The geographical distribution of proton therapy centers plays a role in limited accessibility. Moreover, patients residing in remote or rural areas may face significant challenges in accessing proton therapy due to the distance and lack of nearby facilities. Therefore, limited accessibility is a significant factor hampering market expansion.
Improved design and functionality of proton therapy machines, coupled with sophisticated treatment planning systems, enable healthcare providers to deliver highly targeted radiation doses. The integration of advanced imaging technologies enhances the accuracy of treatment delivery by providing real-time visualization of the tumor and surrounding healthy tissues. Furthermore, software innovations in treatment planning facilitate personalized and adaptive approaches, optimizing proton therapy for individual patient needs. Hence, these technological innovations accelerate market growth.
While proton therapy offers unique advantages, alternative technologies such as intensity-modulated radiation therapy (IMRT) and stereotactic body radiation therapy (SBRT) have also advanced significantly, providing comparable treatment outcomes in certain cases. IMRT, a widely adopted radiation therapy technique, uses multiple beams of radiation that can be adjusted to deliver precise doses to the tumor while minimizing exposure to surrounding healthy tissues. The availability of alternative technologies poses a challenge to market expansion.
The proton therapy systems market has experienced significant impacts from the COVID-19 pandemic. The financial strain on healthcare budgets during the pandemic has influenced investment decisions, potentially slowing down the adoption of proton therapy systems. However, the pandemic has also prompted innovation and adaptation. Telehealth solutions have been increasingly employed for patient consultations and follow-ups. Awareness of the benefits of proton therapy, such as reduced treatment-related side effects, has grown, emphasizing the importance of advanced cancer treatment modalities.
The rotating proton therapy systems segment is estimated to hold the largest share. Rotating proton therapy systems utilize a gantry that can rotate around the patient, providing a three-dimensional approach to irradiating tumours from various angles. This dynamic rotation allows for more precise targeting of cancerous cells while minimizing exposure to healthy tissues. Moreover, the ability to deliver proton beams from multiple directions enables improved conformity to the shape of the tumor, making it particularly effective for complex and irregularly shaped tumours.
The beam delivery system segment is anticipated to have lucrative growth during the forecast period. This system is responsible for directing and controlling the delivery of high-energy proton beams from the proton accelerator to the tumor site within the patient's body. The proton beam's depth and intensity are shaped and modulated by a combination of components, such as energy modulation devices, magnets, and collimators. Furthermore, modern beam delivery systems often incorporate scanning or spot-scanning techniques, allowing for even greater precision by delivering proton beams spot by spot.
North America commanded the largest market share during the extrapolated period. The increasing incidence of cancer, coupled with a growing awareness of the benefits of proton therapy, drives the adoption of these advanced systems. In the United States, the presence of renowned cancer treatment centers and research institutions fosters a climate of innovation and technology adoption, propelling the development and deployment of proton therapy solutions. Additionally, collaborations between academic institutions, healthcare organizations, and industry players contribute to research advancements and the dissemination of best practices in proton therapy.
Europe is expected to witness profitable growth over the projection period. European countries, including Germany, France, the United Kingdom, and others, exhibit a strong demand for proton therapy systems, driven by a rising incidence of cancer and an increasing emphasis on innovative medical technologies. Moreover, the region boasts a network of leading cancer treatment centers and research institutions actively engaged in the development and application of advanced proton therapy solutions.
Some of the key players in the Proton Therapy Systems Market include Mitsubishi Electric Corporation, Mevion Medical Systems, Hitachi, Advanced Oncotherapy plc, Ion Beam Applications SA, IBA worldwide, Varian, Provision Healthcare and ProTom International.
In April 2023, Mitsubishi Electric India CNC has announced partnership with SolidCAM, a global leader in innovative CAM software for CNC machines and distribution of related digital manufacturing solutions.
In August 2022, IBA, the world leader in particle accelerator technology and the world's leading provider of proton therapy solutions for the treatment of cancer, announces it has signed a collaboration agreement with Apollo Hospitals Enterprise Ltd, to provide proton therapy training and education programs for IBA customers in Asia.